A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

被引：0
|
作者：
Pandite, L
Burris, HA
Jones, S
Wilding, G
Taylor, C
Versola, MJ
Smith, DA
Stead, A
Koch, KM
Spector, NL
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Wisconsin Comprehens Canc Ctr, Madison, WI USA
[4] Arizona Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3179
引用
收藏
页码：238S / 238S
页数：1
相关论文
共 50 条
  • [1] A phase I study of Lapatinib (GW572016) and topotecan in patients with solid tumors.
    Erlichman, C
    Adjei, AA
    Joy, ME
    Rubin, SD
    Friedman, RA
    Ames, MM
    Reid, JM
    Molina, JR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8994S - 8994S
  • [2] A phase I study of GW572016 in patients with solid tumors
    Minami, H
    Nakagawa, K
    Kawada, K
    Mukai, H
    Tahara, M
    Kurata, T
    Uejima, H
    Nogami, T
    Sasaki, Y
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [3] Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
    Siegel-Lakhai, Wandena S.
    Beijnen, Jos H.
    Vervenne, Walter L.
    Boot, Henk
    Keessen, Marianne
    Versola, Melissa
    Koch, Kevin M.
    Smith, Deborah A.
    Pandite, Lini
    Richel, Dirk J.
    Schellens, Jan H. M.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4495 - 4502
  • [4] A phase I study of lapatinib (GW572016) and topotecan in patients with solid tumors
    Molina, JRM
    Adjei, AA
    Erlichman, C
    Mandrekar, S
    Joy, ME
    Rubin, SD
    Reid, J
    ANNALS OF ONCOLOGY, 2006, 17 : 49 - 49
  • [5] Clinical activity of GW572016 in EGF10003 inpatients with solid tumors
    Versola, M
    Burris, HA
    Jones, S
    Wilding, G
    Taylor, C
    Pandite, L
    Smith, DA
    Stead, A
    Spector, NL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 206S - 206S
  • [6] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q
    Cianfrocca, ME
    Murray, N
    Oslund, M
    Nelson, LM
    Rowinsky, E
    Schwartz, G
    Goldstein, LJ
    Loftiss, JI
    Paul, E
    Koch, KM
    Pandite, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S235 - S235
  • [7] Safety, tolerability, and pharmacokinetics (PK) of rilotumumab in Japanese patients (pts) with advanced solid tumors.
    Doi, Toshihiko
    Tang, Rui
    Zhang, Yilong
    Loh, Elwyn
    Lizambri, Richard
    Yasui, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab
    Storniolo, AM
    Burris, HA
    Overmoyer, B
    Silverman, P
    Pegram, MD
    Jones, SF
    Peacock, NW
    Loftiss, J
    Koch, KM
    Paul, E
    Ho, PTC
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S64 - S64
  • [9] Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOL-FOX41 in patients with solid tumors.
    Lakhai, WS
    Beijnen, JH
    Den Boer, SS
    Westermann, AM
    Versola, M
    Koch, K
    Ho, P
    Pandite, L
    Richel, DJ
    Schellens, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [10] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients.
    Chu, Q
    Goldstein, L
    Murray, N
    Rowinsky, E
    Cianfrocca, M
    Gale, M
    Ho, P
    Paul, E
    Loftiss, J
    Pandite, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
12345